Regencell Bioscience Limited (RGC) saw its shares plummet by 23.06% in pre-market trading on Wednesday, as investors continued to reassess the company's valuation following a recent stock split announcement. This sharp decline comes after an extraordinary rally that saw the stock surge by an astounding 59,900% year-to-date, despite the company reporting no revenue.

The biotech firm, which specializes in developing traditional Chinese herbal treatments for neurocognitive disorders, recently announced a 38-for-1 forward stock split. While stock splits typically don't affect a company's fundamental value, they often lead to price adjustments as the market recalibrates expectations. In Regencell's case, the split seems to have prompted investors to question the sustainability of the company's lofty valuation, which had briefly surpassed that of established companies like Lululemon, eBay, and Kraft Heinz.

The dramatic sell-off reflects growing investor concerns about Regencell's ability to justify its high valuation with concrete business developments, especially given its lack of revenue. As the market continues to digest the implications of the stock split and reassess Regencell's prospects, the company's stock price may remain volatile in the near term. This recent plunge serves as a stark reminder of the speculative nature of investments in early-stage biotech companies with limited financial track records.